First Pharmaceutical Holdings announced that the Class 1 innovative drug Cantetinib granules independently developed by the company were included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” for the first time through national health insurance negotiations. The medical insurance is classified as a nationally negotiated drug, and the scope of payment is limited to ALK-positive locally advanced or metastatic non-small cell lung cancer patients not treated with ALK inhibitors. The agreement is valid from January 1, 2027 to December 31, 2028. The drug was approved for marketing in June 2026. This inclusion in medical insurance is not expected to have a significant impact on the company's 2026 business performance, and there is uncertainty about future sales.

Zhitongcaijing · 2d ago
First Pharmaceutical Holdings announced that the Class 1 innovative drug Cantetinib granules independently developed by the company were included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” for the first time through national health insurance negotiations. The medical insurance is classified as a nationally negotiated drug, and the scope of payment is limited to ALK-positive locally advanced or metastatic non-small cell lung cancer patients not treated with ALK inhibitors. The agreement is valid from January 1, 2027 to December 31, 2028. The drug was approved for marketing in June 2026. This inclusion in medical insurance is not expected to have a significant impact on the company's 2026 business performance, and there is uncertainty about future sales.